Nicholas Haft is Director at Finch Therapeutics Group, Inc. (FNCH). They have made 2 open-market trades across 1 company since 2021, most recently 2021-12-20.
CIK 0001850404
2 open-market purchases totalling $15.6M since 2021, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| FNCH | 4,056,907 | $7.3M |
Shares reported on the most recent Form 4, priced at the 2021-12-22 close.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.